1-4 of 4
Gijs van de Wetering
Close
Sort by
Journal Articles

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Gilles Salles, Anthony Wang, Alex Mutebi, Abualbishr Alshreef, Kalatu R. Davies, Gijs van de Wetering, Viktor Chirikov
Journal: Blood
Blood (2022) 140 (Supplement 1): 10934–10935.
https://doi.org/10.1182/blood-2022-158028
Published: 2022
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

Anuja Chatterjee, MSc, Gijs Van de Wetering, PhD, Ron Goeree, Anne Marie Desbois, Patricia Manzi, MSc, BPharm, Beenish S Manzoor, PhD, Carolyn Owen, MDFRCPC, Kavita Sail, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-134596
Published: 2020
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 4741.
https://doi.org/10.1182/blood-2019-123706
Published: 2019
Journal Articles

Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial

Istvan Majer, Arun Krishna, Gijs van de Wetering, Jesús F. San-Miguel, MD PhD, Paul G. Richardson
Journal: Blood
Blood (2015) 126 (23): 4504.
https://doi.org/10.1182/blood.V126.23.4504.4504
Published: 2015